The Department of Veterans Affairs now has a rough count of how many veterans might one day be candidates for psychedelic-assisted therapy, and it is far larger than anything the agency expects to serve at first. VA officials told a House Veterans' Affairs subcommittee on Nov. 18 that roughly 180,000 veterans could qualify under preliminary screening criteria. A senior VA adviser had already cautioned that treating even a four-digit number of patients in the first year could be difficult.
That gap between potential demand and early capacity was the thread running through the afternoon hearing, which lasted about two and a half hours.
According to VA officials, about 2.1 million veterans in VA health care have diagnoses involving PTSD, major depressive disorder or treatment-resistant depression. The 180,000 figure reflects the screening criteria used in current research, not eligibility for any approved treatment. No psilocybin or MDMA therapy has FDA approval, and who actually qualifies will depend on which therapies, if any, are approved and on the conditions attached to that approval.
Andrew Gradison, a senior adviser at the Veterans Health Administration, did not give lawmakers a firm first-year capacity number. His earlier comment about a four-digit patient count, made at an October health care forum, was not a formal projection. "If we save one veteran's life next year from these treatments, it's worth it," Gradison told the panel.
Gradison confirmed that the VA has selected 10 facilities for its initial rollout, including sites for clinical treatment and clinician training, but he declined to name all of them publicly. He agreed to give committee members the list within 30 days.
Rep. Herb Conaway, D-N.J., said that from what he had seen, most of the sites were on the coasts, with several in California and others in New Haven, Connecticut, and New York, and none in the Southeast. Dr. Ilse Wiechers, a senior Veterans Health Administration official, said the sites were chosen because the VA judged them most likely to succeed early, and that their experience would guide expansion. The Southeast does have VA research activity in Pscilly's directory, including Birmingham VA Medical Center in Alabama, though it was not identified as one of the 10 sites.
Rep. Maggie Goodlander, D-N.H., asked who would get treatment first if demand outruns appointments, and whether access would depend on living near one of the sites. Gradison said medical ethics, clinical eligibility and patient safety would guide those choices, and that the most experienced VA clinicians would deliver early treatments. Officials acknowledged that geographic access will be limited at first and said the VA is developing standards for referring veterans to community providers.
The treatments are labor intensive. Gradison said dosing sessions alone can run six to eight hours, on top of preparation and follow-up care. Rep. Julia Brownley, D-Calif., the subcommittee's ranking member, asked whether the VA would hire more staff so existing mental health care is not stretched thin. Lawmakers cited a September VA inspector general report in which 58% of reporting facilities said they had severe shortages of psychologists.
Officials also acknowledged that the VA's fiscal 2027 budget did not include a dedicated funding request for psychedelic treatment, though they said existing resources are sufficient. Gradison agreed to deliver a staffing plan within 30 days covering how many clinicians are needed, where they would come from and what it would cost.
Rep. Morgan Luttrell, R-Texas, a longtime supporter of psychedelic treatment for veterans, urged caution, warning that a misstep could end the effort for good.
The VA is already running 21 psychedelic treatment studies, according to officials, and the first randomized MDMA trials for veterans began this year at VA facilities in Rhode Island and Connecticut, including Providence VA Medical Center. In New Haven, Yale Program for Psychedelic Science / Connecticut Mental Health Center is among the region's academic research hubs.
The bigger trigger is at the FDA, where COMPASS Pathways and Usona Institute both have psilocybin applications under review. Even after an approval, psilocybin remains a Schedule I substance, and officials said additional federal and possibly state action would be needed before routine clinical use.
| PTSD, MDD or TRD diagnoses | 2,100,000 veterans |
|---|---|
| Might qualify under preliminary criteria | 180,000 veterans |
VA officials' estimates presented to the House Veterans' Affairs Subcommittee on Health, Nov. 18, 2026. The 180,000 figure uses research screening criteria, not eligibility for an approved treatment.